This article first appeared on GuruFocus .
Release Date: November 17, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Narayana Hrudayalaya Ltd ( BOM:539551 ) reported a significant 70% revenue growth in its Cayman operations, driven by strong performance in the insurance sector.
-
The company has seen a substantial increase in hospital discharges and outpatient services, indicating robust operational growth.
-
The India business reported a 20% EBITDA growth, showcasing strong profitability without the need for additional bed capacity.
-
The company is actively working on optimizing its payer and case mix, leading to improved revenue realizations.
-
Narayana Hrudayalaya Ltd ( BOM:539551 ) is leveraging technology and digital transformation initiatives to enhance operational efficiencies and patient care.
Negative Points
-
The insurance business, while growing, has not yet reached a stable break-even point, with quarter-on-quarter volatility in underwriting performance.
-
The Mumbai hospital is still struggling to break even, with performance fluctuating and requiring strategic adjustments.
-
The international business, particularly in Bangladesh, is not a primary focus and is expected to be wound down over the next few years.
-
There are challenges in integrating new acquisitions, such as the UK operations, with uncertainties around the timeline for achieving meaningful contributions.
-
The company faces difficulties in reporting quarterly results promptly due to the complexity of consolidating international operations.
Q & A Highlights
-
Warning! GuruFocus has detected 1 Warning Sign with BOM:539551.
-
Is BOM:539551 fairly valued? Test your thesis with our free DCF calculator.
Q: Could you explain the significant revenue growth in the Cayman Islands, particularly regarding the insurance product? A: The response to the insurance product has been very positive, with many large employers moving to us or considering it. This has driven aggressive revenue growth. We are still assessing the market share and expect to have a clearer view in 2 to 4 quarters. (Unidentified_5)
Q: With the insurance losses decreasing, can we expect the insurance business to break even in Q3 and move to profits in Q4? A: It's too early to say definitively. As the size of the book grows, underwriting performance stabilizes, but quarter-on-quarter variations make it unreliable to predict exact break-even or profit timelines. (Unidentified_5)
Q: After commissioning the new hospital, should we expect only high single-digit growth, or is there room for higher growth in the next few quarters? A: We have seen a significant jump post-commissioning, with a 50% increase in discharges. There is still growth potential for a couple of quarters before it moderates. We are also focusing on improving profitability. (Unidentified_5)
Q: Can you provide an update on the Mumbai Hospital's financial performance and conversion plans? A: The Mumbai Hospital has been fluctuating in performance, with a slight negative EBITDA this quarter. However, October showed improvement, and we expect a positive Q3. We are also working on transitioning the hospital to include adult programs. (Unidentified_3 and Unidentified_2)
Q: How is the India business performing, particularly in terms of clinics and insurance revenue? A: Both clinics and insurance businesses are showing good momentum. The insurance business is growing, especially with SME offerings, and clinics are balancing profitability with growth investments. We expect this positive trend to continue. (Unidentified_8)
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
